Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.

ABSTRACT: The development of HER2-targeted therapies has dramatically improved patient survival and patient management and increased the quality of life in the HER2+ breast cancer patient population. Due to the activation of compensatory pathways, patients eventually suffer from resistance to HER2-directed therapies and develop a more aggressive disease phenotype. One of these mechanisms is the crosstalk between ER and HER2 signaling, especially the CDK4/6-Cyclin D-Rb signaling axis that is commonly active and has received attention for its potential role in regulating tumor progression. CDK 4/6 inhibitors interfere with the binding of cell-cycle-dependent kinases (CDKs) with their cognate partner cyclins, and forestall the progression of the cell cycle by preventing Rb phosphorylation and E2F relea

SUBMITTER: Koirala N 

PROVIDER: S-EPMC9224522 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature